These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27686391)

  • 1. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease.
    Richmond JM; Bangari DS; Essien KI; Currimbhoy SD; Groom JR; Pandya AG; Youd ME; Luster AD; Harris JE
    J Invest Dermatol; 2017 Feb; 137(2):350-358. PubMed ID: 27686391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and IFN-gamma-inducible alpha-chemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis.
    Klunker S; Trautmann A; Akdis M; Verhagen J; Schmid-Grendelmeier P; Blaser K; Akdis CA
    J Immunol; 2003 Jul; 171(2):1078-84. PubMed ID: 12847282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes.
    Kanda N; Watanabe S
    Endocrinology; 2007 May; 148(5):2317-25. PubMed ID: 17255201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anatomically distinct fibroblast subsets determine skin autoimmune patterns.
    Xu Z; Chen D; Hu Y; Jiang K; Huang H; Du Y; Wu W; Wang J; Sui J; Wang W; Zhang L; Li S; Li C; Yang Y; Chang J; Chen T
    Nature; 2022 Jan; 601(7891):118-124. PubMed ID: 34912121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.
    Rashighi M; Agarwal P; Richmond JM; Harris TH; Dresser K; Su MW; Zhou Y; Deng A; Hunter CA; Luster AD; Harris JE
    Sci Transl Med; 2014 Feb; 6(223):223ra23. PubMed ID: 24523323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.
    Agarwal P; Rashighi M; Essien KI; Richmond JM; Randall L; Pazoki-Toroudi H; Hunter CA; Harris JE
    J Invest Dermatol; 2015 Apr; 135(4):1080-1088. PubMed ID: 25521459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.
    Richmond JM; Strassner JP; Zapata L; Garg M; Riding RL; Refat MA; Fan X; Azzolino V; Tovar-Garza A; Tsurushita N; Pandya AG; Tso JY; Harris JE
    Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity and regulation of CXCL9 and CXCL10 in oral keratinocytes.
    Marshall A; Celentano A; Cirillo N; Mignogna MD; McCullough M; Porter S
    Eur J Oral Sci; 2016 Oct; 124(5):433-439. PubMed ID: 27671889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin.
    Harris JE; Harris TH; Weninger W; Wherry EJ; Hunter CA; Turka LA
    J Invest Dermatol; 2012 Jul; 132(7):1869-76. PubMed ID: 22297636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo.
    Chang Y; Kang P; Cui T; Guo W; Zhang W; Du P; Yi X; Guo S; Gao T; Li C; Li S
    J Transl Med; 2023 Jul; 21(1):434. PubMed ID: 37403086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative increase in regulatory T cells controls development of vitiligo.
    Chatterjee S; Eby JM; Al-Khami AA; Soloshchenko M; Kang HK; Kaur N; Naga OS; Murali A; Nishimura MI; Caroline Le Poole I; Mehrotra S
    J Invest Dermatol; 2014 May; 134(5):1285-1294. PubMed ID: 24366614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of chemokines and the corresponding receptors in vitiligo: A pilot study.
    Yang L; Yang S; Lei J; Hu W; Chen R; Lin F; Xu AE
    J Dermatol; 2018 Jan; 45(1):31-38. PubMed ID: 29115683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo.
    Steitz J; Wenzel J; Gaffal E; Tüting T
    Eur J Cell Biol; 2004 Dec; 83(11-12):797-803. PubMed ID: 15679123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo.
    Wang XX; Wang QQ; Wu JQ; Jiang M; Chen L; Zhang CF; Xiang LH
    Br J Dermatol; 2016 Jun; 174(6):1318-26. PubMed ID: 26801009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
    Qi F; Liu F; Gao L
    Front Immunol; 2021; 12():790125. PubMed ID: 34868078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines.
    Albanesi C; Scarponi C; Sebastiani S; Cavani A; Federici M; De Pità O; Puddu P; Girolomoni G
    J Immunol; 2000 Aug; 165(3):1395-402. PubMed ID: 10903743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding mechanisms of autoimmunity through translational research in vitiligo.
    Strassner JP; Harris JE
    Curr Opin Immunol; 2016 Dec; 43():81-88. PubMed ID: 27764715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.
    Strassner JP; Rashighi M; Ahmed Refat M; Richmond JM; Harris JE
    J Am Acad Dermatol; 2017 May; 76(5):847-855.e5. PubMed ID: 28259440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment.
    Liu H; Wang Y; Le Q; Tong J; Wang H
    Eur J Immunol; 2024 Apr; 54(4):e2250281. PubMed ID: 37937817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of serum CXCL9 and CXCL10 levels in vitiligo patients and their correlation with disease severity and stability: A cross-sectional study.
    Aulakh S; Goel S; Kaur L; Gulati S; Kaur M; Chopra D; Sarangal R; Batra J
    Indian J Dermatol Venereol Leprol; 2024 Jul; ():1-7. PubMed ID: 39152845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.